Pumactant and poractant alfa in respiratory distress syndrome [1] (multiple letters)

Lancet

Volumn 356, Issue 9231, 2000, Pages 765-766

  Morley, Colin ^a   Wardhaugh, Allan D ^b   Matthes, Jean W A ^b   Ainsworth, S B ^c   Beresford, M W ^d   Milligan, D W A ^c   Shaw, N J ^d   Matthews, J N S ^d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b SINGLETON HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; LUNG SURFACTANT;

DRUG COST; GESTATIONAL AGE; INTUBATION; LETTER; MORTALITY; NEWBORN MORTALITY; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS SYNDROME; RESUSCITATION; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HUMAN; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NOTE; RANDOMIZED CONTROLLED TRIAL;

DRUG ADMINISTRATION SCHEDULE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TREATMENT OUTCOME;

EID: 0034718247     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(00)02643-x     Document Type: Letter

References (0)